Introduction: Although more than half of the world's population is already vaccinated, the appearance of new variants of concern puts public health at risk due to the generation of new immunogens against the virus as a crucial and relevant strategy in the control of these new variants.
Methods: A preclinical study used a potential vaccine candidate (RBD, SARS-CoV-2). Four groups of BALB/c mice were used, a control group, an adjuvant group, a group inoculated with one dose of RBD subunit protein, and the fourth group inoculated with two doses of RBD subunit protein.
Results: No inflammatory or cellular changes were shown in the mice's anatomopathological evaluation. Higher kinetics and 75% seroconversion were obtained in the mice inoculated with two doses of RBD (P < 0.0001).
Conclusions: The application of two doses of the RBD vaccine candidate in BALB/c mice proved safe and immunogenic against SARS-CoV-2.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364943 | PMC |
| http://dx.doi.org/10.1016/j.tmaid.2022.102427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Higher vulnerability to poor circadian light hygiene in individuals with a history of COVID-19.
Chronobiol Int
January 2025
Institute of Biology/Zoology, Martin Luther University, Halle-Wittenberg, Germany.
Seven-day actigraphy was performed within 1 month in 122 community-dwelling adults (mean age 24.40 y, 31 (25.4%) men) in the same city of Tyumen, Russia.
View Article and Find Full Text PDFApnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical Trial.
JAMA Pediatr
January 2025
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Importance: Preterm infants are recommended to receive most vaccinations at the same postnatal age as term infants. Studies have inconsistently observed an increased risk for postvaccination apnea in preterm infants.
Objective: To compare the proportions of hospitalized preterm infants with apnea and other adverse events in the 48 hours after 2-month vaccinations vs after no vaccinations.
The emerging of emergent SARS-CoV-2 subvariants has reduced the protective efficacy of COVID-19 vaccines. Therefore, novel COVID-19 vaccines targeting these emergent variants are needed. We designed and prepared CoV072, an mRNA-based vaccine against SARS-CoV-2 Omicron (EG.
View Article and Find Full Text PDFMedical Students' Attitudes Toward the COVID-19 Vaccine and Medical School Vaccine Education: A Survey Study.
Cureus
December 2024
Osteopathic Medicine, Idaho College of Osteopathic Medicine, Meridian, USA.
Objective: The aim of this study is to investigate how demographic factors influence medical students' attitudes toward COVID-19 vaccines and their perceptions of vaccine education in medical school curricula.
Methods: A 28-question anonymous online survey was distributed to 640 medical students at one academic medical institution. Individual attitudes toward vaccines were evaluated using a 5-point Likert scale.
Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Cohort of Healthcare Workers.
Cureus
December 2024
Internal Medicine, Fundació Assistencial Mútua Terrassa, Terrassa, ESP.
In this 13-month follow-up study, we examined a cohort of vaccinated healthcare workers without prior SARS-CoV-2 infection to assess the humoral and cellular response to the BNT162b2 mRNA COVID-19 vaccine over time. We measured median immunoglobulin G and lymphocyte subpopulation levels after the first and second doses, at five months post-second dose, and before and after the third dose. Our findings evinced a remarkable initial cellular and humoral response to each vaccine dose, although a progressive decline suggests the potential need for long-term booster doses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!